Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Net Margin (2018 - 2025)

Historic Net Margin for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to 27.87%.

  • BioNexus Gene Lab's Net Margin rose 232800.0% to 27.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 24.27%, marking a year-over-year decrease of 145600.0%. This contributed to the annual value of 16.81% for FY2024, which is 101000.0% up from last year.
  • BioNexus Gene Lab's Net Margin amounted to 27.87% in Q3 2025, which was up 232800.0% from 27.26% recorded in Q2 2025.
  • BioNexus Gene Lab's 5-year Net Margin high stood at 20.7% for Q4 2021, and its period low was 102.17% during Q3 2023.
  • Its 5-year average for Net Margin is 11.23%, with a median of 3.01% in 2022.
  • As far as peak fluctuations go, BioNexus Gene Lab's Net Margin plummeted by -991700bps in 2023, and later soared by 510300bps in 2024.
  • BioNexus Gene Lab's Net Margin (Quarter) stood at 20.7% in 2021, then plummeted by -109bps to 1.84% in 2022, then surged by 939bps to 15.46% in 2023, then crashed by -189bps to 13.8% in 2024, then crashed by -102bps to 27.87% in 2025.
  • Its Net Margin was 27.87% in Q3 2025, compared to 27.26% in Q2 2025 and 29.17% in Q1 2025.